首页   按字顺浏览 期刊浏览 卷期浏览 Long‐Term Follow‐Up of Zidovudine Therapy in Asymptomatic HIV InfectionRe...
Long‐Term Follow‐Up of Zidovudine Therapy in Asymptomatic HIV InfectionResults of a Multicenter Cohort Study

 

作者: Stefano Vella,   Marina Giuliano,   Leonard Dally,   Maria Agresti,   Carlo Tomino,   Marco Floridia,   Antonio Chiesi,   Vincenzo Fragola,   Mauro Moroni,   Marcello Piazza,   Giorgio Scalise,   Luigi Ortona,   Fernando Aiuti,   Adriano Lazzarin,   Gian Carosi,   Dante Bassetti,   Elio Guzzanti,   Ferdinando Dianzani,  

 

期刊: Journal of Acquired Immune Deficiency Syndromes  (OVID Available online 1994)
卷期: Volume 7, issue 1  

页码: 31-38

 

ISSN:0894-9255

 

年代: 1994

 

出版商: OVID

 

关键词: HIV infection;Asymptomatics;Zidovudine;Progression to AIDS.

 

数据来源: OVID

 

摘要:

SummaryIn 1990 the results of a placebo-controlled study conducted within the AIDS Clinical Trials Group (ACTG 019) showed that in the short term, Zidovudine was effective in slowing progression to advanced disease in HIV-infected asymptomatic patients with low CD4 cell counts. More recently, the preliminary results of the Concorde Trial suggested that while the data at 1 year agreed with those of ACTG 019, no sustained clinical benefit was detectable at 3 years for early versus deferred therapy. Therefore, the length of the clinical usefulness of zidovudine in this population is still to be determined. We evaluated the 2-year outcome of zidovudine therapy in asymptomatic patients through the prospective follow-up of a cohort of 936 subjects with low CD4+(<500/mm3) counts who strictly satisfied, at enrollment, the inclusion and exclusion criteria of the ACTG 019 trial. The clinical end point of the analysis was the development of AIDS. The majority (72.2%) of the individuals in the cohort acquired HIV infection through intravenous drug use; 26.6% were women. The median baseline CD4 cell count was 308/mm3.At 55 weeks of mean follow-up, the progression rate to AIDS (3.2 events per hundred person-years) appears to be comparable to that already reported at the same mean follow-up time for the ACTG 019 zidovudine-treated asymptomatic patients. After 124 weeks of mean follow-up, the overall rate of progression to AIDS was 5.2 per hundred person-years. The majority of those who progressed had CD4+ counts <200/mm3at enrollment and p24 antigenemia and had been treated with high dosages of zidovudine (median dosage: 1,000 mg per day). The analysis of incidence rates over time according to zidovudine dosage group showed that in the low-dosage group (median: 500 mg per day), the progression rate at 124 weeks remained below the rate observed at 55 weeks for the placebo arm of the ACTG 019 study, suggesting that the effect of zidovudine on clinical progression of asymptomatic patients can be sustained for >2 years.

 

点击下载:  PDF (586KB)



返 回